Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study
Gómez, Maria Jose
MetadataShow full item record
Background: The optimal sequence of chemotherapeutic agents is not firmly established for the treatment of metastatic colorectal cancer (mCRC). This phase II multi-centre study investigated the efficacy and tolerability of a standard capecitabine plus irinotecan (XELIRI) regimen with bevacizumab in previously untreated patients with mCRC. Methods: Patients received intravenous irinotecan 175 mg/m2 on day 1 and oral capecitabine 1000 mg/m2 (800 mg/m2 for patients >65 years of age) twice daily on days 2–8, followed by a 1-week rest, and bevacizumab 5 mg/kg as an intravenous infusion on day 1 every 2 weeks. Results: Seventy-seven patients were included in the intention-to-treat and safety populations. Progression-free survival at 9 months was 61%. The overall response and disease control rates were 51% and 84%, respectively. Median progression-free and overall survival times were 11.9 and 24.8 months, respectively. 48 patients (62%) had at least one grade 3/4 adverse event, the most common being asthenia, diarrhoea and neutropenia. Quality of life varied little over the study period with mean visual analogue scale general health scores ranging from 71 to 76 over cycles 1–11. Conclusion: Our study found irinotecan and capecitabine administered fortnightly with bevacizumab in patients with mCRC to be an effective and tolerable regimen. Trial registration: clinicaltrials.gov identifier NCT00875771. Trial registration date: 04/02/2009. Keywords: Irinotecan, Capecitabine, Bevacizumab, Metastatic colorectal cancer, Chemotherapy
Is part ofBMC Cancer, 2015, vol.15, núm. 327
European research projects
The following license files are associated with this item:
Except where otherwise noted, this item's license is described as cc-by, (c) Garcia-Alfonso et al., 2015
Showing items related by title, author, creator and subject.
Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer Feliu, Jaume; Safont, M. J.; Salud Salvia, Maria Antonieta; Losa, F.; García-Girón, C.; Bosch, Carlos; Escudero, P.; López, R.; Madroñal, C.; Bolaños, M.; Gil, M.; Llombart, A.; Castro-Carpeño, J.; González-Barón, M. (Nature Publishing GroupCancer Research UK, 2010)BACKGROUND: The efficacy and safety of capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer (mCRC) considered unsuitable for receiving first-line chemotherapy with an irinotecan or oxaliplatin-based ...
Correlation of hypertension and proteinuria with outcome in elderly bevacizumab treated patients with metastatic colorectal cancer Feliu, Jaume; Salud Salvia, Maria Antonieta; Safont, M. J.; García-Girón, C.; Aparicio, Jorge; Losa, F.; Bosch, Carlos; Escudero, P.; Casado, Enrique; Jorge, Monica; Bohn, Uriel; Pérez-Carrión, Ramon; Carmona, Alberto; Custodio, Ana B.; Maurel, Joan (Public Library of Science, 2015)Background Studies suggest a relationship between hypertension and outcome in bevacizumab-treated patients with metastatic colorectal cancer (mCRC). We performed a retrospective analysis of two phase II studies (BECA ...
A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer Loupakis, Fotios; Stein, Alexander; Ychou, Marc; Hermann, Frank; Salud Salvia, Maria Antonieta; Österlund, Pia (Springer, 2016)Colorectal cancer is the third most common cancer worldwide. A significant proportion of patients presents with unresectable metastatic disease or develops metachronous metastases following surgical resection of the primary ...